


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (original) A compound of formula



wherein

R₁ is halogen or halo(C₁₋₄)alkyl,

R₂ is hydrogen, halogen or halo(C₁₋₄)alkyl,

R₃ is halogen or halo(C₁₋₄)alkyl,

R₄ is hydrogen, (C₁₋₈)alkyl, hydroxy(C₁₋₆)alkyl or a group of formula

- CO-R₅,
- CO-(CH₂)_m-OR₆,
- CO-CO-R₇,
- CO-CO-OR₈,
- CO-N(R₉R₁₀),
- CO-(CH₂)_n-CO-R₁₁,
- CO-(CHR₁₅)-O-(CH₂)_o-CO-R₁₁,
- CO-(CH₂)_p-O-(CH₂)_q-O-(CH₂)_r-R₁₆,
- CO-O-(CH₂)_s-O-CO-R₁₇,
- CO-O-(CH₂)_t-N(R₁₈R₁₉),
- CO-O-(CH₂)_u-NH-CO-CH(NH₂)-R₂₀, or
- CO-O-(CH₂)_w-NH-CO-R₁₇, wherein

R₅ is hydrogen, (C₁₋₈)alkyl, (C₃₋₈)cycloalkyl, amino, (C₁₋₄)alkylamino,

di(C₁₋₄)alkylamino, aryl or heterocyclyl which is a 5 or 6-membered heterocyclic ring system having 1 to 4 heteroatoms selected from N, O or S,

R₆ is hydrogen, (C₁₋₄)alkyl, (C₃₋₈)cycloalkyl, aryl, (C₁₋₄)alkyl substituted by heterocyclyl which is a 5 or 6-membered heterocyclic ring system having 1 to 4 heteroatoms selected from N, O or S, amino(C₁₋₆)alkyl, (C₁₋₄)alkylamino(C₁₋₆)alkyl, di(C₁₋₄)alkylamino(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl,

hydroxy(C₁₋₄)alkylamino(C₁₋₆)alkyl or an amino acid residue,
 e.g. -CH₂-CH(NH₂)-COOH,
 R₇ and R₈ independently of each other are (C₁₋₄)alkyl, (C₃₋₈)cycloalkyl, aryl or heterocyclyl which is a 5 or 6-membered heterocyclic ring system having 1 to 4 heteroatoms selected from N, O or S,
 R₉ and R₁₀ independently of each other are hydrogen or (C₁₋₄)alkyl or one of R₉ and R₁₀ is hydrogen and the other is (C₃₋₈)cycloalkyl, (C₁₋₄)alkyl, aryl or heterocyclyl,
 R₁₁ is (C₁₋₄)alkyl, -OR₁₂, -NR₁₃R₁₄, an amino acid, an (C₁₋₄)alkylester thereof or a di(C₁₋₄)alkylester thereof ,
 R₁₂ is hydrogen or (C₁₋₄)alkyl,
 R₁₃ and R₁₄ independently of each other are hydrogen, (C₁₋₄)alkyl, amino(C₁₋₆)alkyl, (C₁₋₄)alkylamino(C₁₋₆)alkyl, di(C₁₋₄)alkylamino(C₁₋₆)alkyl,
 R₁₅ is hydrogen or (C₁₋₄)alkyl,
 R₁₆ is hydrogen, (C₁₋₄)alkyl, carboxyl or carboxylic ester,
 R₁₇ is amino(C₁₋₄)alkyl, (C₁₋₄)alkylamino(C₁₋₄)alkyl or di(C₁₋₄)alkylamino(C₁₋₄)alkyl,
 R₁₈ is hydrogen or (C₁₋₄)alkyl,
 R₁₉ is hydroxy(C₁₋₄)alkyl,
 R₂₀ is (C₁₋₄)alkyl or hydroxy(C₁₋₄)alkyl,
 m is 0 to 4,
 n is 2 to 8,
 o is 0 to 4,
 p is 0 to 4,
 q is 1 to 8,
 r is 0 to 4,
 s is 1 to 4,
 t is 1 to 4,
 u is 1 to 6 and
 w is 1 to 6.

Claim 2. (original) A compound of claim 1 wherein

- R₁ is chloro or trifluoromethyl,
- R₂ is hydrogen or trifluoromethyl,
- R₃ is chloro, fluoro or trifluoromethyl,
- R₄ is hydrogen, (C₁₋₄)alkyl, e.g. methyl, hydroxy(C₁₋₄)alkyl, e.g. hydroxyethyl, or a group of formula
 - CO-R₅,
 - CO-(CH₂)_m-OR₆,

-CO-CO-R_7 ,
 -CO-CO-OR_8 ,
 $\text{-CO-N(R}_9\text{R}_{10})$,
 $\text{-CO-(CH}_2\text{)}_n\text{-CO-R}_{11}$,
 $\text{-CO-(CHR}_{15}\text{)-O-(CH}_2\text{)}_o\text{-CO-R}_{11}$,
 $\text{-CO-(CH}_2\text{)}_p\text{-O-(CH}_2\text{)}_q\text{-O-(CH}_2\text{)}_r\text{-R}_{16}$,
 $\text{-CO-O-(CH}_2\text{)}_s\text{-O-CO-R}_{17}$,
 $\text{-CO-O-(CH}_2\text{)}_t\text{-N(R}_{18}\text{R}_{19})$,
 $\text{-CO-O-(CH}_2\text{)}_u\text{-NH-CO-CH(NH}_2\text{)-R}_{20}$, or
 $\text{-CO-O-(CH}_2\text{)}_w\text{-NH-CO-R}_{17}$, wherein

R_5 is hydrogen, (C_{1-4}) alkyl, (C_{3-6}) cycloalkyl, dimethylamino, phenyl or heterocyclyl which is a 6-membered heterocyclic ring system having one O as a heteroatom, e.g. tetrahydropyranyl,

R_6 is hydrogen, (C_{1-4}) alkyl, (C_{1-2}) alkyl substituted by heterocyclyl which is a 5 or 6-membered heterocyclic ring system having 1 or 2 heteroatoms selected from N or O, e.g. including unsubstituted pyrrolidine, morpholine and piperazine and piperazine substituted by e.g. (C_{1-2}) alkyl or (C_{1-2}) hydroxyalkyl; amino (C_{1-4}) alkyl, (C_{1-2}) alkylamino (C_{1-4}) alkyl, di (C_{1-2}) alkylamino (C_{1-4}) alkyl, hydroxy (C_{1-3}) alkyl, hydroxy (C_{1-2}) alkylamino (C_{1-2}) alkyl or an amino acid residue, e.g. $\text{-CH}_2\text{-CH(NH}_2\text{)-COOH}$,

R_7 and R_8 independently of each other are (C_{1-2}) alkyl or phenyl,

R_9 and R_{10} independently of each other are hydrogen or (C_{1-2}) alkyl,

R_{11} is (C_{1-2}) alkyl, -OR_{12} , $\text{-NR}_{13}\text{R}_{14}$, an amino acid, an (C_{1-2}) alkylester thereof or an di (C_{1-2}) alkylester thereof, preferably an amino acid selected from the group consisting of alanine, phenylalanine, glutamic acid and lysine, wherein the binding is effected via the α - amino group or in the case of e.g. lysine via the ϵ -amino group,

R_{12} is hydrogen or (C_{1-2}) alkyl,

R_{13} and R_{14} independently of each other are hydrogen, (C_{1-2}) alkyl, amino (C_{1-4}) alkyl, (C_{1-2}) alkylamino (C_{1-4}) alkyl, di (C_{1-2}) alkylamino (C_{1-4}) alkyl,

R_{15} is hydrogen or (C_{1-2}) alkyl,

R_{16} is hydrogen, (C_{1-2}) alkyl, carboxyl or carboxylic ester,

R_{17} is amino (C_{1-2}) alkyl,

R_{18} is hydrogen or (C_{1-2}) alkyl,

R_{19} is hydroxy (C_{1-2}) alkyl,

R_{20} is (C_{1-2}) alkyl or hydroxy (C_{1-2}) alkyl,

m is 0 or 1,

n is 2 to 4,

o is 0 or 1,
p is 0 to 2,
q is 2 to 5,
r is 0 to 2,
s is 2,
t is 2,
u is 1 to 3 and
w is 1 to 3.

Claim 3. (currently amended) A compound according to claim 1-~~or~~2 which is a compound of formula I wherein

R₁ is chloro,
R₂ is hydrogen,
R₃ is trifluoromethyl and
R₄ is hydrogen.

Claim 4. (currently amended) A compound according to claim 1-~~or~~2 which is a compound of formula I wherein

R₁ is chloro,
R₂ is hydrogen,
R₃ is trifluoromethyl and
R₄ is a group of formula $-\text{CO}-\text{O}-(\text{CH}_2)_2-\text{N}[(\text{C}_2\text{H}_5\text{OH})(\text{CH}_3)]$.

Claim 5. (currently amended) A compound according to ~~any one of~~ claims 1-~~to~~4 in the form of a salt.

Claim 6. (canceled).

Claim 7. (currently amended) A method of treatment of IgE-synthesis-mediated diseases, autoimmune diseases, gastrointestinal diseases and chronic rejection of transplants which method comprises administering a therapeutically effective amount of a compound of ~~any one of~~ claims 1-~~to~~5 to a subject in need of such treatment.

Claim 8. (currently amended) A compound of ~~any one of~~ claims 1-~~to~~5 for use as a pharmaceutical.

Claim 9. (currently amended) A pharmaceutical composition comprising a compound of ~~any one of~~ claims 1-~~to~~5 in association with at least one pharmaceutical excipient.

Claim 10. (currently amended) Use of an amine, which is substituted by

- phenyl-substituted pyrimidin; and
- phenyl; and
- a third substituent, e.g. R_4 as defined in claim 1 to 5,

in the preparation of a medicament for the treatment of IgE-synthesis-mediated diseases, autoimmune diseases, gastrointestinal diseases and chronic rejection of transplants.